Assignee
ATEA PHARMACEUTICALS INC
US·25 granted patents·17 pending applications·230 citations·filing 2016–2025
Top patents by PatentIndex Score
42 records- 0198US11738038B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2021·Granted Aug 29, 2023·4 cites·38 claims
- 0298US10894804B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2020·Granted Jan 19, 2021·10 cites·37 claims
- 0398US10875885B2β-d-2′-deoxy-2′-α-fluoro-2′-β-c-substituted-2-modified-n6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 29, 2020·9 cites·24 claims
- 0498US10874687B1Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 29, 2020·34 cites·20 claims
- 0598US10870672B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 22, 2020·9 cites·36 claims
- 0698US10870673B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2020·Granted Dec 22, 2020·9 cites·34 claims
- 0798US10815266B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2019·Granted Oct 27, 2020·10 cites·2 claims
- 0898US10519186B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·24 cites·52 claims
- 0998US9828410B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2016·Granted Nov 28, 2017·28 cites·3 claims
- 1097US12006340B2Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·2 cites·15 claims
- 1197US11813278B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2021·Granted Nov 14, 2023·3 cites·37 claims
- 1297US11707480B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2020·Granted Jul 25, 2023·3 cites·8 claims
- 1397US10239911B2Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2018·Granted Mar 26, 2019·18 cites·24 claims
- 1497US10005811B2β-D-2′-deoxy-2′-α-fluoro-2′β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2017·Granted Jun 26, 2018·19 cites·22 claims
- 1597US10000523B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2017·Granted Jun 19, 2018·20 cites·30 claims
- 1696US12226429B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2023·Granted Feb 18, 2025·1 cites·17 claims
- 1796US12084473B2β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatmentATEA PHARMACEUTICALS INC·Filed 2023·Granted Sep 10, 2024·1 cites·29 claims
- 1896US10906928B2Nucleotide hemi-sulfate salt for the treatment of hepatitis C virusATEA PHARMACEUTICALS INC·Filed 2019·Granted Feb 2, 2021·10 cites·34 claims
- 1995US11975016B22′-substituted-N6-substituted purine nucleotides for RNA virus treatmentATEA PHARMACEUTICALS INC·Filed 2021·Granted May 7, 2024·2 cites·26 claims
- 2093US10946033B22′-substituted-N6-substituted purine nucleotides for RNA virus treatmentATEA PHARMACEUTICALS INC·Filed 2019·Granted Mar 16, 2021·6 cites·23 claims
- 2192US2025243235A1Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6- SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTATEA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2289US11690860B2Treatment of HCV infected patients with cirrhosisATEA PHARMACEUTICALS INC·Filed 2020·Granted Jul 4, 2023·4 cites·37 claims
- 2388US12551499B2Highly active compounds against COVID-19ATEA PHARMACEUTICALS INC·Filed 2023·Granted Feb 17, 2026·0 cites·8 claims
- 2488US10202412B2β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infectionsATEA PHARMACEUTICALS INC·Filed 2017·Granted Feb 12, 2019·4 cites·20 claims
- 2585US2026035404A1Advantageous morphic form of at-527 hemi-sulfate saltATEA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2679US2022267366A1Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatmentATEA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2778US2026091050A1Advantageous anti-hcv combination therapyATEA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 2877US2021277045A1Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2976US2021009628A1Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENTATEA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3075US12458656B2Advantageous anti-HCV combination therapyATEA PHARMACEUTICALS INC·Filed 2025·Granted Nov 4, 2025·0 cites·20 claims
- 3175US2021087217A1Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3274US2023365611A1Advantageous morphic form of at-527 hemi-sulfate saltATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3374US2024148770A1Advantageous anti-hcv combination therapyATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3469US2025109163A1Nucleotide hemi-sulfate salt for the treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3566US2020222442A12'-substituted-n6-substituted purine nucleotides for rna virus treatmentATEA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3665US2024226131A12'-chloro-2'-fluoro-n2-amino-n6-methylamino purine nucleotides for flavivirus treatmentATEA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3763US2025082656A1Dosage regimens for treatment of dengue infectionATEA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3861US2023049294A1Stereoselective process of manufacture of purine phosphoramidatesATEA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3960US2023364121A1Niran interfering drugs for sars-cov-2 mutant therapyATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4060US2023331751A1Stereoselective manufacture of selected purine phosphoramidatesATEA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4145US2020179415A1Highly active drug combination for treatment of hepatitis c virusATEA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4242US10711029B2Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infectionATEA PHARMACEUTICALS INC·Filed 2017·Granted Jul 14, 2020·0 cites·32 claims
Join the waitlist — get patent alerts
Get an alert when ATEA PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →